BI

Boehringer Ingelheim

Every trial this sponsor leads in the registry, and everything it has published.

1,937All trials
Recruiting48
Recruited30
Not yet recruiting9
Completed1,682
Stopped168

87 active · 4% of this sponsor’s registry footprint

Oncology32 trials
Metabolic/Endocrine/Nutrition12 trials
Respiratory10 trials
Renal & Urology5 trials
Cardiovascular4 trials
Ophthalmology4 trials
Gastroenterology & Hepatology3 trials
Immunology & Inflammation3 trials

Not shown above: 10 Phase 1 healthy-volunteer trials and 3 trials whose condition matched no therapy area.

Trials by phase

Phase 11,074
Phase 2307
Phase 3387
Phase 4126
Unphased43

Pipeline by phase · 38 drugs in active development

Phase 3 · 9 drugs

Obrixtamig (BI 764532)11 trials · 5 recruitingest. Sept 2026
Nerandomilast7 trials · 5 recruitingest. Apr 2027
zongertinib6 trials · 4 recruitingest. Dec 2026
Survodutide (BI 456906)5 trials · 3 recruitingest. Jan 2027
Verducatib (BI 1291583)5 trials · 3 recruitingest. Dec 2026
Vicadrostat (BI 690517)4 trials · 4 recruitingest. May 2028
Empagliflozin3 trials · 1 recruitingest. Mar 2027
BI 7641982 trials · 2 recruitingest. Jan 2028

Phase 2 · 10 drugs

BI 30002023 trials · 3 recruitingest. Oct 2026
BI 30347013 trials · 1 recruitingest. Dec 2026
BI 15848621 trialest. Dec 2026
BI 18153681 trial · 1 recruitingest. Sept 2027
BI 3032950 intravenous (Part A)1 trial · 1 recruitingest. Jul 2027
BI 38028761 trial · 1 recruitingest. Aug 2027
BI 7645241 trialest. Mar 2027
BI 7654231 trial · 1 recruitingest. Mar 2027

Phase 1 · 19 drugs

BI 7703712 trialsest. Aug 2027
BI 17019631 trialest. Mar 2028
BI 17038801 trial · 1 recruitingest. Sept 2028
BI 18239111 trialest. Nov 2026
BI 3000202_low dose1 trialest. Dec 2026
BI 37209311 trialest. Oct 2040
BI 37765281 trial · 1 recruitingest. Feb 2027
BI 38043791 trial · 1 recruitingest. Feb 2028

Not counted above: 1 unphased intervention.

Active trials only, code names and brands merged. 1,682 completed trials are in the counts above but their drugs are not folded into this pipeline.

Disease landscapes · 5 of 10 curated

Non-small cell lung cancer (Oncology)4 trials · 1 recruiting · 3 drugs0.3% of landscape
Obesity (Metabolic & Nutrition)4 trials · 2 recruiting · 2 drugs0.4% of landscape
Type 2 diabetes (Endocrinology)2 trials · 2 recruiting · 2 drugs0.2% of landscape
Breast cancer (Oncology)1 trial · 1 recruiting · 1 drug<0.1% of landscape
Ulcerative colitis (Gastroenterology & Hepatology)1 trial · 1 recruiting · 1 drug0.6% of landscape

Active trials judged against ten curated disease boundaries; the share compares this company's active trials with the landscape's industry-wide total. Activity outside these landscapes appears in the therapy-area split above.

Track your drug now for free

We check every one of its trials daily and tell you what moved.

  • Status changeStatus moved to completedWas recruiting · always alerts
  • Completion date movePrimary completion slipped 210 daysSlips and pull-ins of 30+ days
  • New trialNew trial registered in your scopeFirst posted within 30 days
  • Enrollment changeEnrollment grew to 1,200Moves of 15%+ or count finalised
  • Substantive record editPrimary endpoint redefined from 24 to 52 weeksRead overnight and flagged in plain English
US registryClinicalTrials.gov
EU registryCTIS · Soon